Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Vile

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 18, 2005
Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?P Hatfield, A Merrick, K Harrington, et al.
Human Gene Therapy|December 10, 1999
Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancerS Todryk, C McLean, S Ali, et al.
Gene Therapy|May 7, 2010
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?T Pencavel, R Seth, A Hayes, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Recent clinical experience with oncolytic virusesO G Donnelly, F Errington-Mais, R Prestwich, et al.
Human Gene Therapy|May 8, 2001
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomasE Galanis, A Bateman, K Johnson, et al.
Gene Therapy|December 18, 2009
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaF Galivo, R M Diaz, P Wongthida, et al.
Gene Therapy|August 19, 2003
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapyA Ahmed, D Jevremovic, K Suzuki, et al.
Gene Therapy|May 26, 2006
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatmentJ Qiao, J Moreno, L Sanchez-Perez, et al.
Blood|June 5, 2001
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient miceD Grote, S J Russell, T I Cornu, et al.
Gene Therapy|April 21, 2006
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particlesT Kottke, J Qiao, R M Diaz, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 18, 2005
Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?P Hatfield, A Merrick, K Harrington, et al.
Human Gene Therapy|December 10, 1999
Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancerS Todryk, C McLean, S Ali, et al.
Gene Therapy|May 7, 2010
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?T Pencavel, R Seth, A Hayes, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Recent clinical experience with oncolytic virusesO G Donnelly, F Errington-Mais, R Prestwich, et al.
Human Gene Therapy|May 8, 2001
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomasE Galanis, A Bateman, K Johnson, et al.
Gene Therapy|December 18, 2009
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanomaF Galivo, R M Diaz, P Wongthida, et al.
Gene Therapy|August 19, 2003
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapyA Ahmed, D Jevremovic, K Suzuki, et al.
Gene Therapy|May 26, 2006
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatmentJ Qiao, J Moreno, L Sanchez-Perez, et al.
Blood|June 5, 2001
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient miceD Grote, S J Russell, T I Cornu, et al.
Gene Therapy|April 21, 2006
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particlesT Kottke, J Qiao, R M Diaz, et al.
Pageof 5